共 63 条
- [1] Jacobzone S., Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals [Occasional Paper No. 40], (2000)
- [2] Leibowitz A., Manning W., Newhouse J., The demand for prescription drugs as a function of cost sharing, Soc Sci Med, 21, pp. 1063-1069, (1985)
- [3] Soumerai S.B., Avorn J., Ross-Degnan D., Et al., Payment restrictions for drugs under Medicaid: Effects on therapy, cost and equity, N Engl J Med, 317, pp. 550-556, (1987)
- [4] O'Brien B., The effect of patient charges on the utilisation of prescription medicines, J Health Econ, 8, pp. 109-132, (1989)
- [5] Harris B.L., Stergachis A., Ried L.D., The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization, Med Care, 28, pp. 907-917, (1990)
- [6] Ryan M., Birch S., Charging for health care: Evidence on the utilization of NHS prescribed medicines, Soc Sci Med, 33, pp. 681-687, (1991)
- [7] Huttin C., The use of prescription charges, Health Policy, 27, pp. 53-73, (1994)
- [8] Hughes D., McGuire A., Patient charges and the utilization of NHS prescription medicines: Some estimates using a cointegration procedure, Health Econ, 4, pp. 213-220, (1995)
- [9] Tamblyn R., Laprise R., Hanley J.A., Et al., Adverse events associated with prescription drug cost-sharing among poor and elderly persons, JAMA, 285, pp. 421-429, (2001)
- [10] Atella V., Drug cost containment policies in Italy: Are they really effective in the long-run? The case of minimum reference price, Health Policy, 50, pp. 197-218, (1999)